NCT06219733 2024-12-09
MP-VAC-206
MedPacto, Inc.
Phase 2 Withdrawn
Clinical Trials
10 trialsNCT03688568 2021-02-12
Study of Imatinib in Children With Neurofibromatosis and Airway Tumors
Indiana University
Phase 2 Withdrawn
NCT02538926 2018-11-14
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
Phase 2 Withdrawn
NCT02812693 2018-04-05
Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
Ohio State University Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT00324077 2016-02-17
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT02268435 2015-08-04
Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors
Asan Medical Center
Phase 1 Withdrawn
NCT01188889 2015-05-15
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
University of Michigan Rogel Cancer Center
Phase 1/2 Withdrawn
NCT01011998 2011-09-27
A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)
New Mexico Cancer Research Alliance
Phase 2 Withdrawn
NCT00159016 2011-04-28
Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.
Hadassah Medical Organization
Phase 2 Withdrawn
NCT00594555 2008-10-31
A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia
University of Cincinnati
Phase 2 Withdrawn